nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—sarcoma	0.0269	0.0695	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—TLE1—sarcoma	0.0177	0.0458	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MITF—sarcoma	0.0155	0.0399	CbGpPWpGaD
Methsuximide—Proteinuria—Mitoxantrone—sarcoma	0.0146	0.0238	CcSEcCtD
Methsuximide—Protein urine present—Mitoxantrone—sarcoma	0.0144	0.0235	CcSEcCtD
Methsuximide—Photophobia—Thiotepa—sarcoma	0.0139	0.0227	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—PLCG1—sarcoma	0.0102	0.0263	CbGpPWpGaD
Methsuximide—Ataxia—Thiotepa—sarcoma	0.0101	0.0165	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—CREB1—sarcoma	0.00935	0.0242	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—EZR—sarcoma	0.00903	0.0233	CbGpPWpGaD
Methsuximide—Ataxia—Vincristine—sarcoma	0.00899	0.0147	CcSEcCtD
Methsuximide—Pancytopenia—Thiotepa—sarcoma	0.00884	0.0144	CcSEcCtD
Methsuximide—Pancytopenia—Dactinomycin—sarcoma	0.00878	0.0143	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—MYOG—sarcoma	0.00851	0.022	CbGpPWpGaD
Methsuximide—Stevens-Johnson syndrome—Dactinomycin—sarcoma	0.00817	0.0133	CcSEcCtD
Methsuximide—Haematuria—Thiotepa—sarcoma	0.00792	0.0129	CcSEcCtD
Methsuximide—Pancytopenia—Vincristine—sarcoma	0.00784	0.0128	CcSEcCtD
Methsuximide—Pancytopenia—Mitoxantrone—sarcoma	0.00764	0.0125	CcSEcCtD
Methsuximide—Weight decreased—Vincristine—sarcoma	0.00747	0.0122	CcSEcCtD
Methsuximide—Weight decreased—Mitoxantrone—sarcoma	0.00728	0.0119	CcSEcCtD
Methsuximide—Drowsiness—Mitoxantrone—sarcoma	0.00717	0.0117	CcSEcCtD
Methsuximide—Erythema multiforme—Dactinomycin—sarcoma	0.007	0.0114	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—CREB1—sarcoma	0.00689	0.0178	CbGpPWpGaD
Methsuximide—Haematuria—Mitoxantrone—sarcoma	0.00684	0.0112	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—CREB1—sarcoma	0.00667	0.0172	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—EZR—sarcoma	0.00666	0.0172	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—EZR—sarcoma	0.00645	0.0167	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—EZR—sarcoma	0.00645	0.0167	CbGpPWpGaD
Methsuximide—Tension—Thiotepa—sarcoma	0.00637	0.0104	CcSEcCtD
Methsuximide—Pancytopenia—Etoposide—sarcoma	0.00635	0.0104	CcSEcCtD
Methsuximide—Nervousness—Thiotepa—sarcoma	0.0063	0.0103	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—MYOG—sarcoma	0.00627	0.0162	CbGpPWpGaD
Methsuximide—Vision blurred—Thiotepa—sarcoma	0.00612	0.00998	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—MYOG—sarcoma	0.00607	0.0157	CbGpPWpGaD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—SRC—sarcoma	0.00603	0.0156	CbGpPWpGaD
Methsuximide—Hiccups—Epirubicin—sarcoma	0.00598	0.00975	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Etoposide—sarcoma	0.00591	0.00965	CcSEcCtD
Methsuximide—Leukopenia—Thiotepa—sarcoma	0.00581	0.00948	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—NRAS—sarcoma	0.0058	0.015	CbGpPWpGaD
Methsuximide—Leukopenia—Dactinomycin—sarcoma	0.00577	0.00941	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—sarcoma	0.00563	0.0146	CbGpPWpGaD
Methsuximide—Hiccups—Doxorubicin—sarcoma	0.00553	0.00902	CcSEcCtD
Methsuximide—Confusional state—Thiotepa—sarcoma	0.00534	0.00871	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—PTPRC—sarcoma	0.00532	0.0138	CbGpPWpGaD
Methsuximide—Vision blurred—Mitoxantrone—sarcoma	0.00528	0.00862	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—MYOD1—sarcoma	0.00525	0.0136	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CREB1—sarcoma	0.00524	0.0135	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—PLCG1—sarcoma	0.00521	0.0135	CbGpPWpGaD
Methsuximide—Leukopenia—Vincristine—sarcoma	0.00515	0.0084	CcSEcCtD
Methsuximide—Erythema multiforme—Etoposide—sarcoma	0.00506	0.00826	CcSEcCtD
Methsuximide—Anorexia—Thiotepa—sarcoma	0.00505	0.00824	CcSEcCtD
Methsuximide—Leukopenia—Mitoxantrone—sarcoma	0.00502	0.00818	CcSEcCtD
Methsuximide—Anorexia—Dactinomycin—sarcoma	0.00501	0.00817	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—KRAS—sarcoma	0.00499	0.0129	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—EZR—sarcoma	0.00475	0.0123	CbGpPWpGaD
Methsuximide—Somnolence—Thiotepa—sarcoma	0.00471	0.00768	CcSEcCtD
Methsuximide—Confusional state—Mitoxantrone—sarcoma	0.00461	0.00752	CcSEcCtD
Methsuximide—Decreased appetite—Thiotepa—sarcoma	0.0046	0.00751	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—EZR—sarcoma	0.0046	0.0119	CbGpPWpGaD
Methsuximide—Gastrointestinal disorder—Thiotepa—sarcoma	0.00457	0.00746	CcSEcCtD
Methsuximide—Decreased appetite—Dactinomycin—sarcoma	0.00457	0.00745	CcSEcCtD
Methsuximide—Constipation—Thiotepa—sarcoma	0.00453	0.00739	CcSEcCtD
Methsuximide—Anorexia—Vincristine—sarcoma	0.00448	0.0073	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—SRC—sarcoma	0.00445	0.0115	CbGpPWpGaD
Methsuximide—Feeling abnormal—Thiotepa—sarcoma	0.00436	0.00712	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—sarcoma	0.00436	0.0113	CbGpPWpGaD
Methsuximide—Anorexia—Mitoxantrone—sarcoma	0.00436	0.00711	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—sarcoma	0.00435	0.0112	CbGpPWpGaD
Methsuximide—Feeling abnormal—Dactinomycin—sarcoma	0.00433	0.00707	CcSEcCtD
Methsuximide—Gastrointestinal pain—Thiotepa—sarcoma	0.00433	0.00707	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—sarcoma	0.00432	0.0112	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—SRC—sarcoma	0.00431	0.0111	CbGpPWpGaD
Methsuximide—Gastrointestinal pain—Dactinomycin—sarcoma	0.0043	0.00701	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—NRAS—sarcoma	0.00428	0.0111	CbGpPWpGaD
Methsuximide—Insomnia—Vincristine—sarcoma	0.00425	0.00693	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—HRAS—sarcoma	0.00424	0.011	CbGpPWpGaD
Methsuximide—Urticaria—Thiotepa—sarcoma	0.00421	0.00686	CcSEcCtD
Methsuximide—Abdominal pain—Thiotepa—sarcoma	0.00419	0.00683	CcSEcCtD
Methsuximide—Leukopenia—Etoposide—sarcoma	0.00417	0.00681	CcSEcCtD
Methsuximide—Abdominal pain—Dactinomycin—sarcoma	0.00416	0.00678	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—NRAS—sarcoma	0.00414	0.0107	CbGpPWpGaD
Methsuximide—Decreased appetite—Vincristine—sarcoma	0.00408	0.00666	CcSEcCtD
Methsuximide—Ataxia—Epirubicin—sarcoma	0.00408	0.00666	CcSEcCtD
Methsuximide—Somnolence—Mitoxantrone—sarcoma	0.00407	0.00663	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Vincristine—sarcoma	0.00405	0.00661	CcSEcCtD
Methsuximide—Constipation—Vincristine—sarcoma	0.00402	0.00655	CcSEcCtD
Methsuximide—Decreased appetite—Mitoxantrone—sarcoma	0.00398	0.00649	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—PTPRC—sarcoma	0.00392	0.0101	CbGpPWpGaD
Methsuximide—Constipation—Mitoxantrone—sarcoma	0.00391	0.00638	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—IL2—sarcoma	0.00387	0.01	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MYOD1—sarcoma	0.00387	0.01	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—PLCG1—sarcoma	0.00384	0.00992	CbGpPWpGaD
Methsuximide—Gastrointestinal pain—Vincristine—sarcoma	0.00384	0.00626	CcSEcCtD
Methsuximide—Confusional state—Etoposide—sarcoma	0.00384	0.00626	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—PTPRC—sarcoma	0.0038	0.00982	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—PTPRC—sarcoma	0.0038	0.00982	CbGpPWpGaD
Methsuximide—Ataxia—Doxorubicin—sarcoma	0.00378	0.00616	CcSEcCtD
Methsuximide—CYP2C19—Melatonin metabolism and effects—FOXO1—sarcoma	0.00377	0.00974	CbGpPWpGaD
Methsuximide—Feeling abnormal—Mitoxantrone—sarcoma	0.00377	0.00615	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—MYOD1—sarcoma	0.00375	0.00969	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CTNNB1—sarcoma	0.00374	0.00967	CbGpPWpGaD
Methsuximide—Gastrointestinal pain—Mitoxantrone—sarcoma	0.00374	0.0061	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—PLCG1—sarcoma	0.00372	0.00961	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—PLCG1—sarcoma	0.00372	0.00961	CbGpPWpGaD
Methsuximide—Eosinophilia—Epirubicin—sarcoma	0.00371	0.00606	CcSEcCtD
Methsuximide—Abdominal pain—Vincristine—sarcoma	0.00371	0.00606	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—KRAS—sarcoma	0.00368	0.00951	CbGpPWpGaD
Methsuximide—Urticaria—Mitoxantrone—sarcoma	0.00363	0.00593	CcSEcCtD
Methsuximide—Anorexia—Etoposide—sarcoma	0.00363	0.00592	CcSEcCtD
Methsuximide—Diarrhoea—Thiotepa—sarcoma	0.00362	0.00591	CcSEcCtD
Methsuximide—Abdominal pain—Mitoxantrone—sarcoma	0.00362	0.0059	CcSEcCtD
Methsuximide—Diarrhoea—Dactinomycin—sarcoma	0.0036	0.00587	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—KRAS—sarcoma	0.00357	0.00921	CbGpPWpGaD
Methsuximide—Pancytopenia—Epirubicin—sarcoma	0.00356	0.00581	CcSEcCtD
Methsuximide—Dizziness—Thiotepa—sarcoma	0.0035	0.00571	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—sarcoma	0.0035	0.00904	CbGpPWpGaD
Methsuximide—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.00348	0.009	CbGpPWpGaD
Methsuximide—Eosinophilia—Doxorubicin—sarcoma	0.00344	0.0056	CcSEcCtD
Methsuximide—Weight decreased—Epirubicin—sarcoma	0.00339	0.00553	CcSEcCtD
Methsuximide—Somnolence—Etoposide—sarcoma	0.00338	0.00552	CcSEcCtD
Methsuximide—Vomiting—Thiotepa—sarcoma	0.00337	0.00549	CcSEcCtD
Methsuximide—Drowsiness—Epirubicin—sarcoma	0.00334	0.00545	CcSEcCtD
Methsuximide—Vomiting—Dactinomycin—sarcoma	0.00334	0.00545	CcSEcCtD
Methsuximide—Rash—Thiotepa—sarcoma	0.00334	0.00545	CcSEcCtD
Methsuximide—Dermatitis—Thiotepa—sarcoma	0.00334	0.00544	CcSEcCtD
Methsuximide—Headache—Thiotepa—sarcoma	0.00332	0.00541	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.00332	0.00541	CcSEcCtD
Methsuximide—Rash—Dactinomycin—sarcoma	0.00331	0.00541	CcSEcCtD
Methsuximide—Decreased appetite—Etoposide—sarcoma	0.00331	0.0054	CcSEcCtD
Methsuximide—Pancytopenia—Doxorubicin—sarcoma	0.0033	0.00538	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Etoposide—sarcoma	0.00328	0.00536	CcSEcCtD
Methsuximide—Constipation—Etoposide—sarcoma	0.00325	0.00531	CcSEcCtD
Methsuximide—Diarrhoea—Vincristine—sarcoma	0.00321	0.00524	CcSEcCtD
Methsuximide—Haematuria—Epirubicin—sarcoma	0.00319	0.0052	CcSEcCtD
Methsuximide—Nausea—Thiotepa—sarcoma	0.00315	0.00513	CcSEcCtD
Methsuximide—Weight decreased—Doxorubicin—sarcoma	0.00314	0.00512	CcSEcCtD
Methsuximide—Feeling abnormal—Etoposide—sarcoma	0.00314	0.00511	CcSEcCtD
Methsuximide—Diarrhoea—Mitoxantrone—sarcoma	0.00313	0.00511	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—HRAS—sarcoma	0.00313	0.00809	CbGpPWpGaD
Methsuximide—Nausea—Dactinomycin—sarcoma	0.00312	0.00509	CcSEcCtD
Methsuximide—Gastrointestinal pain—Etoposide—sarcoma	0.00311	0.00508	CcSEcCtD
Methsuximide—Dizziness—Vincristine—sarcoma	0.00311	0.00507	CcSEcCtD
Methsuximide—Drowsiness—Doxorubicin—sarcoma	0.00309	0.00505	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.00307	0.005	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—KDR—sarcoma	0.00306	0.0079	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—HRAS—sarcoma	0.00303	0.00783	CbGpPWpGaD
Methsuximide—Urticaria—Etoposide—sarcoma	0.00302	0.00493	CcSEcCtD
Methsuximide—Abdominal pain—Etoposide—sarcoma	0.00301	0.00491	CcSEcCtD
Methsuximide—Vomiting—Vincristine—sarcoma	0.00299	0.00487	CcSEcCtD
Methsuximide—Rash—Vincristine—sarcoma	0.00296	0.00483	CcSEcCtD
Methsuximide—Dermatitis—Vincristine—sarcoma	0.00296	0.00483	CcSEcCtD
Methsuximide—Haematuria—Doxorubicin—sarcoma	0.00295	0.00481	CcSEcCtD
Methsuximide—Headache—Vincristine—sarcoma	0.00294	0.0048	CcSEcCtD
Methsuximide—Vomiting—Mitoxantrone—sarcoma	0.00291	0.00474	CcSEcCtD
Methsuximide—Rash—Mitoxantrone—sarcoma	0.00288	0.0047	CcSEcCtD
Methsuximide—Dermatitis—Mitoxantrone—sarcoma	0.00288	0.0047	CcSEcCtD
Methsuximide—Headache—Mitoxantrone—sarcoma	0.00287	0.00467	CcSEcCtD
Methsuximide—Erythema multiforme—Epirubicin—sarcoma	0.00284	0.00463	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—PTPRC—sarcoma	0.0028	0.00724	CbGpPWpGaD
Methsuximide—Nausea—Vincristine—sarcoma	0.00279	0.00455	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—PLCG1—sarcoma	0.00274	0.00708	CbGpPWpGaD
Methsuximide—Nausea—Mitoxantrone—sarcoma	0.00272	0.00443	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—PTPRC—sarcoma	0.00271	0.00701	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—CREB1—sarcoma	0.00268	0.00693	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—PLCG1—sarcoma	0.00265	0.00686	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—FOXO1—sarcoma	0.00264	0.00682	CbGpPWpGaD
Methsuximide—Erythema multiforme—Doxorubicin—sarcoma	0.00263	0.00428	CcSEcCtD
Methsuximide—Diarrhoea—Etoposide—sarcoma	0.0026	0.00425	CcSEcCtD
Methsuximide—Tension—Epirubicin—sarcoma	0.00256	0.00418	CcSEcCtD
Methsuximide—Nervousness—Epirubicin—sarcoma	0.00254	0.00414	CcSEcCtD
Methsuximide—Dizziness—Etoposide—sarcoma	0.00252	0.0041	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—MMP2—sarcoma	0.0025	0.00645	CbGpPWpGaD
Methsuximide—Vision blurred—Epirubicin—sarcoma	0.00246	0.00402	CcSEcCtD
Methsuximide—Vomiting—Etoposide—sarcoma	0.00242	0.00395	CcSEcCtD
Methsuximide—Rash—Etoposide—sarcoma	0.0024	0.00391	CcSEcCtD
Methsuximide—Dermatitis—Etoposide—sarcoma	0.0024	0.00391	CcSEcCtD
Methsuximide—Headache—Etoposide—sarcoma	0.00238	0.00389	CcSEcCtD
Methsuximide—Tension—Doxorubicin—sarcoma	0.00237	0.00387	CcSEcCtD
Methsuximide—Nervousness—Doxorubicin—sarcoma	0.00235	0.00383	CcSEcCtD
Methsuximide—Leukopenia—Epirubicin—sarcoma	0.00234	0.00382	CcSEcCtD
Methsuximide—Vision blurred—Doxorubicin—sarcoma	0.00228	0.00372	CcSEcCtD
Methsuximide—Nausea—Etoposide—sarcoma	0.00226	0.00369	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—KDR—sarcoma	0.00225	0.00582	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—KDR—sarcoma	0.00218	0.00564	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—KDR—sarcoma	0.00218	0.00564	CbGpPWpGaD
Methsuximide—Leukopenia—Doxorubicin—sarcoma	0.00216	0.00353	CcSEcCtD
Methsuximide—Confusional state—Epirubicin—sarcoma	0.00215	0.00351	CcSEcCtD
Methsuximide—Anorexia—Epirubicin—sarcoma	0.00203	0.00332	CcSEcCtD
Methsuximide—Confusional state—Doxorubicin—sarcoma	0.00199	0.00325	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—CREB1—sarcoma	0.00198	0.00511	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—FOXO1—sarcoma	0.00194	0.00503	CbGpPWpGaD
Methsuximide—Insomnia—Epirubicin—sarcoma	0.00193	0.00315	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—CREB1—sarcoma	0.00191	0.00495	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—CREB1—sarcoma	0.00191	0.00494	CbGpPWpGaD
Methsuximide—Somnolence—Epirubicin—sarcoma	0.0019	0.00309	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—FOXO1—sarcoma	0.00188	0.00487	CbGpPWpGaD
Methsuximide—Anorexia—Doxorubicin—sarcoma	0.00188	0.00307	CcSEcCtD
Methsuximide—Decreased appetite—Epirubicin—sarcoma	0.00185	0.00302	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Epirubicin—sarcoma	0.00184	0.003	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—MMP2—sarcoma	0.00184	0.00475	CbGpPWpGaD
Methsuximide—Constipation—Epirubicin—sarcoma	0.00182	0.00297	CcSEcCtD
Methsuximide—Insomnia—Doxorubicin—sarcoma	0.00178	0.00291	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—MMP2—sarcoma	0.00178	0.0046	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MMP2—sarcoma	0.00178	0.0046	CbGpPWpGaD
Methsuximide—Feeling abnormal—Epirubicin—sarcoma	0.00176	0.00287	CcSEcCtD
Methsuximide—Somnolence—Doxorubicin—sarcoma	0.00175	0.00286	CcSEcCtD
Methsuximide—Gastrointestinal pain—Epirubicin—sarcoma	0.00174	0.00284	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—SRC—sarcoma	0.00173	0.00447	CbGpPWpGaD
Methsuximide—Decreased appetite—Doxorubicin—sarcoma	0.00172	0.0028	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Doxorubicin—sarcoma	0.0017	0.00278	CcSEcCtD
Methsuximide—Urticaria—Epirubicin—sarcoma	0.00169	0.00276	CcSEcCtD
Methsuximide—Constipation—Doxorubicin—sarcoma	0.00169	0.00275	CcSEcCtD
Methsuximide—Abdominal pain—Epirubicin—sarcoma	0.00169	0.00275	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—VEGFA—sarcoma	0.00168	0.00435	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—NRAS—sarcoma	0.00166	0.0043	CbGpPWpGaD
Methsuximide—Feeling abnormal—Doxorubicin—sarcoma	0.00163	0.00265	CcSEcCtD
Methsuximide—Gastrointestinal pain—Doxorubicin—sarcoma	0.00161	0.00263	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—KDR—sarcoma	0.00161	0.00416	CbGpPWpGaD
Methsuximide—Urticaria—Doxorubicin—sarcoma	0.00157	0.00256	CcSEcCtD
Methsuximide—Abdominal pain—Doxorubicin—sarcoma	0.00156	0.00254	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—KDR—sarcoma	0.00156	0.00403	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—EGFR—sarcoma	0.00152	0.00392	CbGpPWpGaD
Methsuximide—Diarrhoea—Epirubicin—sarcoma	0.00146	0.00238	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—KRAS—sarcoma	0.00143	0.0037	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CREB1—sarcoma	0.00141	0.00364	CbGpPWpGaD
Methsuximide—Dizziness—Epirubicin—sarcoma	0.00141	0.0023	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—CREB1—sarcoma	0.00137	0.00353	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—CTNNB1—sarcoma	0.00137	0.00353	CbGpPWpGaD
Methsuximide—Vomiting—Epirubicin—sarcoma	0.00136	0.00221	CcSEcCtD
Methsuximide—Diarrhoea—Doxorubicin—sarcoma	0.00135	0.0022	CcSEcCtD
Methsuximide—Rash—Epirubicin—sarcoma	0.00134	0.00219	CcSEcCtD
Methsuximide—Dermatitis—Epirubicin—sarcoma	0.00134	0.00219	CcSEcCtD
Methsuximide—Headache—Epirubicin—sarcoma	0.00134	0.00218	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—MMP2—sarcoma	0.00131	0.00339	CbGpPWpGaD
Methsuximide—Dizziness—Doxorubicin—sarcoma	0.0013	0.00213	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—SRC—sarcoma	0.00128	0.00329	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MMP2—sarcoma	0.00127	0.00329	CbGpPWpGaD
Methsuximide—Nausea—Epirubicin—sarcoma	0.00127	0.00207	CcSEcCtD
Methsuximide—Vomiting—Doxorubicin—sarcoma	0.00125	0.00205	CcSEcCtD
Methsuximide—Rash—Doxorubicin—sarcoma	0.00124	0.00203	CcSEcCtD
Methsuximide—Dermatitis—Doxorubicin—sarcoma	0.00124	0.00203	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—VEGFA—sarcoma	0.00124	0.00321	CbGpPWpGaD
Methsuximide—Headache—Doxorubicin—sarcoma	0.00124	0.00202	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—SRC—sarcoma	0.00123	0.00319	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—SRC—sarcoma	0.00123	0.00319	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—NRAS—sarcoma	0.00123	0.00317	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—HRAS—sarcoma	0.00122	0.00315	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—VEGFA—sarcoma	0.0012	0.00311	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—VEGFA—sarcoma	0.0012	0.00311	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—NRAS—sarcoma	0.00119	0.00307	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—NRAS—sarcoma	0.00119	0.00307	CbGpPWpGaD
Methsuximide—Nausea—Doxorubicin—sarcoma	0.00117	0.00191	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—EGFR—sarcoma	0.00112	0.00289	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—EGFR—sarcoma	0.00108	0.0028	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—EGFR—sarcoma	0.00108	0.0028	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—KRAS—sarcoma	0.00106	0.00273	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—KRAS—sarcoma	0.00102	0.00264	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—KRAS—sarcoma	0.00102	0.00264	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CTNNB1—sarcoma	0.00101	0.0026	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—CTNNB1—sarcoma	0.000975	0.00252	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—SRC—sarcoma	0.00091	0.00235	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—HRAS—sarcoma	0.000897	0.00232	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—VEGFA—sarcoma	0.000886	0.00229	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—SRC—sarcoma	0.000881	0.00228	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—NRAS—sarcoma	0.000875	0.00226	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—HRAS—sarcoma	0.000869	0.00225	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—HRAS—sarcoma	0.000869	0.00224	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—VEGFA—sarcoma	0.000858	0.00222	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—NRAS—sarcoma	0.000848	0.00219	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—EGFR—sarcoma	0.000798	0.00206	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—EGFR—sarcoma	0.000772	0.002	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—KRAS—sarcoma	0.000753	0.00195	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—KRAS—sarcoma	0.00073	0.00189	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—HRAS—sarcoma	0.00064	0.00165	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—HRAS—sarcoma	0.00062	0.0016	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ENO2—sarcoma	0.000258	0.000666	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HBA1—sarcoma	0.000256	0.000662	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PLCG1—sarcoma	0.000219	0.000565	CbGpPWpGaD
